1.. Introduction {#s6}
================

About 20-30% of patients with schizophrenia are classified as 'refractory schizophrenia'.\[[@B1]\] The original diagnostic criteria for refractory schizophrenia proposed by Kane in 1995\[[@B2],[@B3]\] were as follows: 1) partially nonresponsive over the past 5 years when treated with three kinds of antipsychotic medications (at least two of which were of different chemical structures) which were administered at appropriate dosages for a sufficient duration; 2) intolerance of side effects of the antipsychotic medications; and 3) relapse or symptomatic deterioration even when taking sufficient doses of appropriate medication. Other widely accepted criteria of refractory schizophrenia include a duration of illness of more than five years; psychiatric symptoms that show no improvement after two-years of regular, full dose and full course treatment with two kinds of antipsychotics; and no response to clozapine.\[[@B2]\]

The difficulty of treating patients with refractory schizophrenia can lead to a poor quality of life for affected individuals.\[[@B3]\] Clozapine is considered an effective medicine for most patients with refractory schizophrenia, but another therapeutic option considered in several studies is the combined use of antipsychotic medication and electroconvulsive therapy (ECT).\[[@B1]\] However, the findings from these studies have been inconsistent: compared to continued use of standard antipsychotic medications,some studies find the combined use of antipsychotic medication and ECT beneficial,some find it no different,and some find it inferior due to the increased occurrence of memory loss and headache.\[[@B4]\] This paper reports on the first known systematic review and meta-analysis on this topic, combining studies reported both in English and in Chinese.

2.. Methods {#s7}
===========

2.1. Search strategy {#s7a}
--------------------

We searched the following databases for studies published before May 1, 2015: Pubmed, Excerpta Medica dataBASE (EMBASE), The Cochrane Library, EBSCO, Chinese National Knowledge Infrastructure (CNKI), Chongqing VIP database for Chinese Technical Periodicals, WANFANG DATA, Chinese Biological Medical Literature Database, Taiwan Electronic Periodical Services, and ClinicalTrials.gov. We used the keywords 'refractory', 'schizophrenia', 'psychosis', 'electric shock', 'electroconvulsive', 'clinical control study', 'randomly, placebo',and 'randomly, trial' (and the Chinese equivalents) in the searches. Various combinations of these keywords were used to search for articles, reference lists of included articles were hand-checked for further relevant studies, and experts in the field were asked about ongoing studies.

2.2. Inclusion and exclusion criteria {#s7b}
-------------------------------------

All reports of randomized controlled trails (RCTs) about the combined treatment of refractory schizophrenia with antipsychotic medications and ECT were screened using the following inclusion criteria: a) a diagnosis of refractory (or 'treatment-resistant') schizophrenia made by psychiatrists; b) the control group was treated with antipsychotic medications; and c) the intervention group was treated with antipsychotic medication and ECT. Studies published in either English or Chinese were considered. Observational studies, anthropologic studies, review articles, research protocols, case reports, and duplicated reports were excluded.

2.3. Screening of articles {#s7c}
--------------------------

All search results were imported into Endnote X5 software. Two authors (WWZ and PCC) independently screened titles and abstracts after eliminating duplicates. The full texts of the remaining articles were screened according to the above inclusion and exclusion criteria. When the two authors disagreed about the inclusion of an article and were unable to agree after discussing the article, a third author (LCB) made the final determination. As shown in Figure 1, 22 studies were included in the final analysis.

![Identification of included studies](sap-27-04-206-g003){#sap-27-04-206-g003.tiff}

2.4. Evaluation of risk of bias {#s7d}
-------------------------------

Two authors (WWZ and PCC) assessed the risk of bias independently for all included articles using the Cochrane Risk of Bias (RoB)\[[@B5]\] tool which considers seven specific items: random sequence generation; allocation concealment; blinding of participants and treating clinicians about group assignment; blinding of evaluators of outcomes about group assignment; incomplete data (attrition and exclusions); selective outcome reporting; and other biases (including study-specific biases or concerns about fraudulent results). Each aspect was rated as 'low risk of bias', 'high risk of bias', or 'unclear' (if insufficient information was provided in the article to make a determination). A third author's (LCB) opinion was sought when the two raters disagreed.

We also evaluated the quality and level of evidence of each outcome variable for each of the 22 included studies using the Cochrane collaboration's Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) software. This software assesses limitations of the design, consistency of results, indirect evidence, precision of results, publication bias, and effect size for each outcome.\[[@B5],[@B6]\] The overall level of evidence is rated as 'high', 'medium', 'low', or 'very low'.

2.5. Outcome measures {#s7e}
---------------------

This meta-analysis was conducted to assess the efficacy and safety of the combination of antipsychotic medication and ECT in the treatment of patients with refractory schizophrenia. The primary outcome measure of effectiveness was the reduction in the total score of the main scale used to assess psychiatric symptoms during treatment. The primary outcome measure of adverse events was based on the score of the Treatment Emergent Symptom Scale (TESS). Secondary outcomes were the changes of cognitive and overall functioning after treatment.

2.6. Data extraction {#s7f}
--------------------

For each included study, two authors (WWZ and PCC) independently extracted data using a pre-designed data extraction form including the names of authors, publication year, sample size, number of outcome events, age of participants, and types of antipsychotics used. Discrepancies between the two coders were checked by a third author (LCB).

2.7. Analysis {#s7g}
-------------

Based on the results of a previous study about risk of bias,\[[@B25]\] the overall risk of bias for each of the 22 studies was classified as 'low' if the ratings were 'low' for all seven items on the ROB tool, 'unclear' if any item is rated as 'unclear' and all other items are rated as 'low', and 'high' if any of the items are rated as 'high'. The kappa statistic was used to measure the inter-rater agreement between the two independent raters for the ratings of each item and for the overall rating.\[[@B7]\] Review Manager (RevMan 5.3) was used to estimate pooled the mean difference (MD) when the same continuous measure was used as the outcome measure in all included studies, the standard mean difference (SMD) when different continuous measures were used as outcome measures in included studies,and risk ratios (RR) for outcomes that were categorical measures. Heterogeneity was measured using I^2^.\[[@B8]\] When I^2^ is less than 50% and p\>0.10, the results were considered homogeneous and the fixed-effect model was used; when I^2^ is greater than 50% but less than 75%, results were considered heterogeneous and the random-effect model was used. If I^2^ is 75% or greater, we conducted sensitivity analysis to identify potential contributors to heterogeneity; if I^2^ remained 75% or greater after removing outliers, we only provided descriptive results without pooling estimates. A funnel plot was used to evaluate potential publication bias.\[[@B5]\]

3.. Results {#s8}
===========

3.1. Characteristics of included studies {#s8a}
----------------------------------------

As shown in Figure 1, we identified a total of 1065 articles in the selected databases. After removing 166 duplicated articles using Endnote X5 software, there were 899 unduplicated reports. Based on the inclusion and exclusion criteria, 773 articles were excluded by reading the title and abstract and a further 104 were excluded by reading the full text. The remaining 22 articles\[[@B9],[@B10],[@B11],[@B12],[@B13],[@B14],[@B15],[@B16],[@B17],[@B18],[@B19],[@B20],[@B21],[@B22],[@B23],[@B26],[@B27],[@B28],[@B29],[@B30],[@B31],[@B32]\] were included in the subsequent analyses: 18 (81.8%) were from China \[[@B10],[@B12],[@B13],[@B14],[@B15],[@B16],[@B18],[@B19],[@B20],[@B21],[@B22],[@B26],[@B27],[@B28],[@B29],[@B30],[@B31],[@B32]\] and 4 (18.2%) from other countries; \[[@B9],[@B11],[@B17],[@B23]\] all were published between 1999 and 2015.

The characteristics of these 22 included studies are shown in Tables 1 and 2.

a\) Definition of refractory schizophrenia: The inclusion and exclusion criteria varied across studies, but most studies used either the diagnostic criteria for schizophrenia established by the Chinese Society of Psychiatry (CCMD)\[[@B33]\] or the diagnostic criteria for schizophrenia developed by the American Psychiatric Association (DSM-IV),\[[@B34]\] required a duration of illness of at least 2 years (with one exception\[[@B9]\]), and required unsatisfactory clinical results when previously using at least two types of antipsychotic medications.

b\) Gender of participants: One study\[[@B32]\] only included females, but all other studies\[[@B9],[@B10],[@B11],[@B12],[@B13],[@B14],[@B15],[@B16],[@B17],[@B18],[@B19],[@B20],[@B21],[@B22],[@B23],[@B26],[@B27],[@B28],[@B29],[@B30],[@B31]\] included both males and females.

c\) Age of participants: Three studies\[[@B9],[@B17],[@B27]\] did not describe the age of participants; the remaining 19 studies\[[@B10],[@B11],[@B12],[@B13],[@B14],[@B15],[@B16],[@B18],[@B19],[@B20],[@B21],[@B22],[@B23],[@B26],[@B28],[@B29],[@B30],[@B31],[@B32]\] were conducted with adults ranging from 18 to 74 years of age.

d\) Duration of illness: Among the 17 studies that provided the mean duration of illness among participants,\[[@B9],[@B11],[@B12],[@B13],[@B15],[@B17],[@B18],[@B19],[@B22],[@B23],[@B26],[@B27],[@B28],[@B29],[@B30],[@B31],[@B32]\] the range in the mean duration of illness was from 6 to 21 years.

e\) Type of antipsychotic medication used in study: All participants received antipsychotic medications either alone or in combination with ECT. The medications employed included clozapine, olanzapine, risperidone,quetiapine, ziprasidone, chlorpromazine,and flupenthixol.

f\) ECT sessions: Two studies\[[@B9],[@B17]\] did not provide information on the number of ECT sessions; the remaining studies\[[@B10],[@B11],[@B12],[@B13],[@B14],[@B15],[@B16],[@B18],[@B19],[@B20],[@B21],[@B22],[@B23],[@B24],[@B25],[@B26],[@B27],[@B28],[@B29],[@B30],[@B31],[@B32]\] reported using 6 to 24 ECT sessions. Among the 18 studies\[[@B10],[@B11],[@B12],[@B13],[@B14],[@B15],[@B16],[@B18],[@B20],[@B21],[@B22],[@B23],[@B26],[@B27],[@B28],[@B29],[@B30],[@B31],[@B32]\] that provided information on ECT frequency, the range in frequency was from three sessions per week to two sessions per month. Only eight studies\[[@B11],[@B12],[@B13],[@B17],[@B22],[@B23],[@B28],[@B31]\] reported on the type of ECT stimulus,which was either bilateral or bitemporal.

g\) Outcome measures: Standard measures of psychiatric symptoms,primarily the Positive and Negative Syndrome Scale (PANSS)\[[@B35]\] and the Brief Psychiatric Rating Scale (BPRS),\[[@B36]\] were used to assess effectiveness,though the criteria used to determine clinical improvement varied somewhat across studies. Overall adverse events were assessed using TESS\[[@B37]\] in six studies.\[[@B10],[@B13],[@B18],[@B20],[@B28],[@B30]\] Five studies reported results of cognitive functioning: two studies\[[@B11],[@B23]\] used the Mini-Mental State Examination (MMSE),\[[@B41]\] one study\[[@B18]\] used the Wisconsin Card Sorting Test (WCST),\[[@B42]\] and two studies\[[@B19],[@B31]\] used the Wechsler Memory Scale (WMS).\[[@B43]\] Overall functioning was assessed using the Global Assessment of Functioning (GAF)\[[@B38]\] in three studies\[[@B11],[@B18],[@B28]\] and the Clinical Global Impression score (CGI) \[[@B44]\] in one study.\[[@B17]\]

h\) Duration of follow-up: One study\[[@B26]\] did not provide information about the duration of follow-up; one study\[[@B14]\] had a 3 to 5 week follow-up; four studies\[[@B17],[@B21],[@B27],[@B31]\] followed patients for 4 weeks; nine studies\[[@B9],[@B10],[@B15],[@B19],[@B20],[@B22],[@B23],[@B30],[@B32]\] followed patients for 8 weeks; six studies\[[@B12],[@B13],[@B16],[@B18],[@B28],[@B29]\] followed patients for 12 weeks; and one study\[[@B11]\] followed patients for 24 weeks.

###### 

Characteristics of 22 randomized controlled trials that compare treatment of refractory schizophrenia with combined ECT and antipsychotic medication versus treatment with antipsychotic medication alone

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  study                       [treatment]{.ul}\                                   [age]{.ul}\               [sample size]{.ul}\       trial duration\   number of ECT sessions   blind evaluation   outcome measures\
                              ECT group/control group                             ECT group/control group   ECT group/control group   (weeks)                                                       (change required for 'improvement')
  --------------------------- --------------------------------------------------- ------------------------- ------------------------- ----------------- ------------------------ ------------------ -------------------------------------
  Chanpatana 1999\[[@B11]\]   ECT+flupenthixol/flupenthixol                       20-49                     17/18                     24                14                       yes                BPRS; GAF; MMSE

  Goswami 2003\[[@B17]\]      ECT+chlorpromazine/sham ECT+chlorpromazine          NA                        15/10                     4                 NA                       yes                BPRS(20%) and CGI≤3 or BPRS≤35

  Yang 2005\[[@B27]\]         ECT+clozapine/clozapine                             NA                        30/30                     4                 6-12                     NA                 PANSS(20%)

  Ding 2007\[[@B13]\]         ECT+risperidone/risperidone                         36.5/38.7                 30/30                     12                ≥12                      NA                 PANSS(20%); TESS

  Cai 2008\[[@B10]\]          ECT+clozapine/clozapine                             18-60                     50/50                     8                 6-12                     NA                 BPRS(25%); TESS

  Braga 2009\[[@B9]\]         ECT+clozapine/clozapine                             NA                        21/17                     8                 NA                       NA                 BPRS(20%)

  Jiang 2009\[[@B18]\]        ECT+risperidone/risperidone                         38.3/39.7                 34/35                     12                8-12                     NA                 PANSS(50%); TESS; WCST; GAF

  Zhou 2009\[[@B31]\]         ECT+olanzepine/olanzepine                           43.1/42.2                 31 /32                    4                 8-12                     NA                 PANSS(25%); WMS

  liu 2010a\[[@B21]\]         ETC+various antipsychotics/various antipsychotics   38.4/39.4                 37/33                     4                 12                       NA                 SANS(50%); SAPS(50%)

  Liu 2010b\[[@B22]\]         ECT+risperidone/clozapine                           28.6/29.6                 30/30                     8                 ≥12                      NA                 PANSS(25%)

  Ding 2011\[[@B14]\]         ETC+various antipsychotics/various antipsychotics   29.8/31.5                 100/100                   3-5               9-15                     NA                 PANSS(50%)

  Du 2011\[[@B15]\]           ECT+clozapine/clozapine                             38.6                      30/30                     8                 10                       NA                 BPRS (25%)

  Duo 2003\[[@B16]\]          ECT+olanzepine/olanzepine                           43.8/42.7                 30/30                     12                8-12                     NA                 PANSS (25%)

  Jiang 2011\[[@B19]\]        ECT+various antipsychotics/various antipsychotics   43.4                      23/23                     8                 17-24                    NA                 PANSS (50%); WMS

  Yang 2011\[[@B28]\]         ECT+risperidone/risperidone                         18-65                     35/36                     12                12                       NA                 PANSS (25%); GAF; TESS

  Chen 2012\[[@B29]\]         ECT+clozapine/clozapine                             31.9/33.6                 36/35                     12                7-12                     NA                 PANSS (25%)

  Wang 2012\[[@B32]\]         ECT+quetapine/quetapine                             28.9/29.3                 31/31                     8                 10                       NA                 PANSS (25%)

  Zhang 2012\[[@B30]\]        ECT+olanzepine/olanzepine                           38.4                      42/42                     8                 16                       NA                 PANSS (25%); TESS

  Chen 2013\[[@B12]\]         ECT+various antipsychotics/various antipsychotics   18-60                     50/40                     12                8-12                     NA                 PANSS (25%)

  Jiang 2013\[[@B20]\]        ECT+ziprasidone/ziprasidone+clozapine               21-74                     81/81                     8                 12                       NA                 BPRS (25%); TESS

  Wang 2013\[[@B26]\]         ECT+olanzepine/olanzepine                           45.5                      36/36                     NA                10-12                    NA                 PANSS (25%)

  Petrides 2015\[[@B23]\]     ECT+clozapine/clozapine                             18-60                     20/19                     8                 20                       yes                BPRS (40%); MMSE
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ECT, electroconvulsive therapy

NA, data not available

BPRS, Brief Psychiatric Rating Scale\[[@B36]\]

GAF, Global Assessment of Functioning\[[@B38]\]

MMSE, Mini-Mental Status Exam\[[@B41]\]

PANSS,Positive and Negative Syndrome Scale\[[@B35]\]

CGI, Clinical Global Impression\[[@B44]\]

TESS, Treatment Emergent Symptoms Scale\[[@B37]\]

WCST,Wisconsin Card Sort Test\[[@B42]\]

WMS, Weschler Memory Scale\[[@B43]\]

SANS, Scale for Assessment of Negative Symptoms\[[@B40]\]

SAPS, Scale for Assessment of Positive Symptoms\[[@B39]\]

^a^ only had female participants

###### 

Supplemental information for the 22 studies included in the systematic review

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  study                      definition of 'treatment refractory schizophrenia'   [mean (sd) years of illness]{.ul}\   type of ECT stimulus   ECT frequency                                                         
                                                                                  ECT group /control group                                                                                                          
  -------------------------- ---------------------------------------------------- ------------------------------------ ---------------------- --------------- -------------- ------------------------- ------------ -----------
  Chanpatana1999\[[@B11]\]   NA                                                   ≥2                                   \>750                  ≥2 years        BPRS\>35       13.7 (5.5)/14.2 (6.4)     bilateral    2-4/month

  Goswami 2003\[[@B17]\]     DSM-IV                                               ≥3                                   \>1000                 ≥5 years        NA             7.6/6.9                   bitemporal   NA

  Yang 2005\[[@B27]\]        CCMD-3                                               ≥3                                   NA                     ≥5 years        PANSS\>60      6.3 (4.3)/6.0 (4.9)       NA           3/week

  Ding 2007\[[@B13]\]        CCMD-3                                               ≥3                                   \>450                  ≥5 years        PANSS\>65      9.7 (11.0)/9.7 (10.4)     bitemporal   1-2/week

  Cai 2008\[[@B10]\]         CCMD-3                                               ≥3                                   \>600                  NA              BPRS\>50       1-10^a^                   NA           3/week

  Braga 2009\[[@B9]\]        NA                                                   NA                                   \>250                  ≥8 weeks        NA             NA                        NA           NA

  Jiang 2009\[[@B18]\]       CCMD-3                                               ≥3                                   NA                     ≥5 years        PANSS≥60       12.6 (5.1)/12.4 (5.0)     NA           2-3/week

  Zhou 2009\[[@B31]\]        CCMD-3                                               ≥3                                   \>600                  ≥5 years        PANSS≥60       21.0 (7.8)/19.4 (9.9)     bitemporal   2-3/week

  Liu 2010a\[[@B21]\]        CCMD-3                                               NA                                   NA                     NA              NA             NA                        NA           3/week

  Liu 2010b\[[@B22]\]        CCMD-3                                               ≥3                                   NA                     ≥5 years        PANSS≥60       8.3 (4.2)/8.0 (3.2)       bitemporal   1-3/week

  Ding 2011\[[@B14]\]        CCMD-3                                               ≥3                                   NA                     NA              NA             NA                        NA           3/week

  Du 2011\[[@B15]\]          CCMD-3                                               ≥3                                   \>1000                 ≥5 years        BPRS≥45        10.0 (4.0)                NA           NA

  Duo 2011\[[@B16]\]         NA                                                   NA                                   NA                     NA              NA             17.5 (5.6)/18.6 (4.2)     NA           2-3/week

  Jiang 2011\[[@B19]\]       CCMD-3                                               ≥2                                   NA                     ≥2 years        PANSS≥60       7.5 (7.6)                 NA           NA

  Yang 2011\[[@B28]\]        CCMD-3                                               ≥3                                   NA                     ≥5 years        PANSS≥60,      11.2 (5.2)/10.3 (4.9)     bitemporal   2-3/week

  Chen 2012\[[@B29]\]        CCMD-3                                               ≥2                                   \>600                  ≥5 years        PANSS\>60      16.1 (11.6)/15.8 (11.2)   NA           2-3/week

  Wang 2012\[[@B32]\]        CCMD-3                                               ≥2                                   \>600                  ≥5 years        PANSS≥60       8.7                       NA           3/week

  Zhang 2012\[[@B30]\]       CCMD-3                                               ≥3                                   NA                     ≥5 years        PANSS\>60      NA                        NA           1-3/week

  Chen 2013\[[@B12]\]        CCMD-3                                               ≥3                                   NA                     ≥5 years        PANSS\>60      9.0 (1.7)/8.5 (0.9)       bitemporal   2-3/week

  Jiang 2013\[[@B20]\]       CCMD-2-R                                             ≥3                                   NA                     NA              NA             7.9                       NA           1-3/week

  Wang 2013\[[@B26]\]        CCMD-3                                               ≥3                                   NA                     ≥5 years        NA             13.2 (5.2)                NA           3/week

  Petrides 2015\[[@B23]\]    DSM-IV                                               ≥2                                   \>600                  ≥2 years        BPRS; CGI^b^   NA                        bilateral    2-3/week
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ECT, electroconvulsive therapy

NA, data not available

BPRS, Brief Psychiatric Rating Scale\[[@B36]\]

PANSS, Positive and Negative Syndrome Scale\[[@B35]\]

CGI, Clinical Global Impression\[[@B44]\]

DSM-IV, 4th edition of Diagnostic and Statistical Manual for mental disorders\[[@B34]\]

CCMD-3, 3rd edition of Chinese Classification of Mental Disorders\[[@B33]\]

CCMD-2-R, Revised 2nd edition of Chinese Classification of Mental Disorders\[[@B33]\]

^a^ range (not mean) in duration of illness

^b^ one of the four psychotic items of BPRS≥4 or total score≥12; and CGI≥4

3.2. Risk of bias and publication bias {#s8b}
--------------------------------------

The results of the assessment of risk of bias in the 22 studies are shown in Table 3. Most of the studies, particularly those from China,did not provide sufficient details about the methods used in the study,so the majority of the assessments for the seven items included in the Risk of Bias (ROB) tool\[[@B5]\] were rated as 'uncertain'. One study\[[@B17]\] used sham ECT and, thus, was double-blind; two other studies\[[@B11],[@B23]\] used blinded outcome evaluators; and one study\[[@B23]\] reported that the participants and treating clinicians were not blinded; but none of the other studies provided information about blinding of the participant, the treating clinician, or the outcome evaluator. Only two studies\[[@B17],[@B18]\] described the method of randomization. Overall, one study\[[@B23]\] was rated as 'high' risk of bias and the other studies were all rated as 'uncertain' risk of bias; none of the studies were classified as being at low-risk of bias. The inter-rater reliability of the two independent coders' assessment of overall risk of bias in the studies was acceptable (kappa=0.75).

###### 

Evaluation of risk of bias in the 22 included studies based on the seven items in the Cochrane Risk of Bias (RoB) tool

  study                       random sequence generation   allocation concealment   blinding of participants and providers   blinding of outcome assessment   incomplete outcome data   selective reporting   other biases^a^   overall risk of bias^b^
  --------------------------- ---------------------------- ------------------------ ---------------------------------------- -------------------------------- ------------------------- --------------------- ----------------- -------------------------
  Chanpatana 1999\[[@B11]\]   Unclear                      Low                      Unclear                                  Low                              Low                       Unclear               Unclear           **Unclear**
  Goswami 2003\[[@B17]\]      Low                          Low                      Low                                      Low                              Low                       Unclear               Unclear           **Unclear**
  Yang 2005\[[@B27]\]         Unclear                      Unclear                  Unclear                                  Unclear                          Unclear                   Unclear               Unclear           **Unclear**
  Ding 2007\[[@B13]\]         Unclear                      Unclear                  Unclear                                  Unclear                          Unclear                   Unclear               Unclear           **Unclear**
  Cai 2008\[[@B10]\]          Unclear                      Unclear                  Unclear                                  Unclear                          Unclear                   Unclear               Unclear           **Unclear**
  Braga 2009\[[@B9]\]         Unclear                      Unclear                  Unclear                                  Unclear                          Unclear                   Unclear               Unclear           **Unclear**
  Jiang 2009\[[@B18]\]        Low                          Unclear                  Unclear                                  Unclear                          Low                       Unclear               Unclear           **Unclear**
  Zhou 2009\[[@B31]\]         Unclear                      Unclear                  Unclear                                  Unclear                          Unclear                   Unclear               Unclear           **Unclear**
  Liu 2010a\[[@B21]\]         Unclear                      Unclear                  Unclear                                  Unclear                          Low                       Unclear               Unclear           **Unclear**
  Liu 2010b\[[@B22]\]         Unclear                      Unclear                  Unclear                                  Unclear                          Unclear                   Unclear               Unclear           **Unclear**
  Ding 2011\[[@B14]\]         Unclear                      Unclear                  Unclear                                  Unclear                          Low                       Unclear               Unclear           **Unclear**
  Du 2011\[[@B15]\]           Unclear                      Unclear                  Unclear                                  Unclear                          Unclear                   Unclear               Unclear           **Unclear**
  Duo 2011\[[@B16]\]          Unclear                      Unclear                  Unclear                                  Unclear                          Unclear                   Unclear               Unclear           **Unclear**
  Jiang 2011\[[@B19]\]        Unclear                      Unclear                  Unclear                                  Unclear                          Unclear                   Unclear               Unclear           **Unclear**
  Yang 2011\[[@B28]\]         Unclear                      Unclear                  Unclear                                  Unclear                          Low                       Unclear               Unclear           **Unclear**
  Chen 2012\[[@B29]\]         Unclear                      Unclear                  Unclear                                  Unclear                          Unclear                   Unclear               Unclear           **Unclear**
  Wang 2012\[[@B32]\]         Unclear                      Unclear                  Unclear                                  Unclear                          Unclear                   Unclear               Unclear           **Unclear**
  Zhang 2012\[[@B30]\]        Unclear                      Unclear                  Unclear                                  Unclear                          Unclear                   Unclear               Unclear           **Unclear**
  Chen 2013\[[@B12]           Unclear                      Unclear                  Unclear                                  Unclear                          Unclear                   Unclear               Unclear           **Unclear**
  Jiang 2013\[[@B20]\]        Unclear                      Unclear                  Unclear                                  Unclear                          Unclear                   Unclear               Unclear           **Unclear**
  Wang 2013\[[@B26]\]         Unclear                      Unclear                  Unclear                                  Unclear                          Unclear                   Unclear               Unclear           **Unclear**
  Petrides 2015\[[@B23]\]     Unclear                      Unclear                  High                                     Low                              Low                       Unclear               Unclear           **High**
  **kappa^c^**                **1.00**                     **1.00**                 **0.49**                                 **0.82**                         **1.00**                  **1.00**              **1.00**          **0.75**

^a^ Other biases considered include including study-specific biases or concerns about fraudulent results

^b^ If any of seven items are coded high-risk of bias the overall study is classified as high-risk, if all seven items are coded as low-risk the overall study is classified as low-risk; all other studies (i.e., those with some items coded 'unclear' and no items coded as high-risk) are classified as 'unclear'

^c^ Weighted kappa values for inter-rater reliability of the two independent coders who assessed each item for the 23 studies

The funnel plot of the primary outcome of efficacy provided by 18 of the studies\[[@B9],[@B10],[@B12],[@B13],[@B14],[@B15],[@B16],[@B18],[@B19],[@B20],[@B22],[@B23],[@B26],[@B27],[@B29],[@B30],[@B31],[@B32]\] is shown in Figure 2. There is substantial publication bias; the three smaller studies\[[@B9],[@B19],[@B23]\] were more likely to find a significant advantage for combined treatment with ECT plus antipsychotic medications versus the sole use of antipsychotic medications in the treatment of refractory schizophrenia.

![Funnel plot of publication bias based on the primary outcome measure of efficacy in 18 of the 22 included studies](sap-27-04-206-g004){#sap-27-04-206-g004.tiff}

As shown in Table 4, based on the GRADE criteria the overall quality of the evidence about effectiveness (defined as percent of patients who showed 'improvement' by the end of the trial) was rated as 'moderate', but the quality of evidence about general side effects (assessed using TESS), cognitive functioning, and overall functioning was rated as 'very low'. The six studies that provided data about general side effects based on the TESS score\[[@B10],[@B13],[@B18],[@B20],[@B28],[@B30]\] had very heterogeneous results and, thus, could not be pooled in a meta-analysis.

###### 

Summary of meta-analysis and GRADE assessments of quality of data about different outcome measures of randomized compared trials comparing ECT and antipsychotic medication versus medication alone in the treatment of treatment refractory schizophrenia

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  outcomes             number of studies\   test for heterogeneity   analytic model   test for overall effect   estimate   95% confidence interval of estimate   GRADE                      
                       (pooled sample)                                                                                                                                                      
  -------------------- -------------------- ------------------------ ---------------- ------------------------- ---------- ------------------------------------- ------------- ------------ ----------
  effectiveness        18 (1394)            38%                      0.05             fixed                     7.51       \<0.001                               1.31 (RR)     1.22-1.41    moderate

  side effect (TESS)   6 (534)              81%                      \< 0.01          \-                        \-         \-                                    \-            \-           very low

  cognitive function   4 (199)              65%                      0.04             random                    1.14       0.25                                  -0.28 (SMD)   -0.77-0.20   very low

  overall function     3 (157)              48%                      0.14             fixed                     7.26       \<0.01                                10.25 (MD)    7.48-13.01   very low
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GRADE, Grades of Recommendation, Assessment, Development, and Evaluation

ECT, electroconvulsive therapy

TESS, Treatment Emergent Symptom Scale\[[@B37]\]

RR, risk ratio

SMD, standardized mean difference

MD, mean difference

3.3. Efficacy {#s8c}
-------------

Eighteen studies with a pooled sample of 1394 participants provided information on efficacy (i.e., percent of cases that achieved the study-specific criteria for 'improvement') at the end of the trial.\[[@B9],[@B10],[@B12],[@B13],[@B14],[@B15],[@B16],[@B18],[@B19],[@B20],[@B22],[@B23],[@B26],[@B27],[@B29],[@B30],[@B31],[@B32]\] The I^2^ was satisfactory but the corresponding p-value was too small to justify considering the results of the various studies homogeneous (I^2^=38%, p=0.05), so a random-effect model was conducted. The result, shown in Figure 3, indicate that patients with refractory schizophrenia treated with the combination of ECT and antipsychotic medications are more likely to experience symptomatic improvement than patients treated with antipsychotic medications alone (RR=1.25, 95% CI =1.14-1.37).

![Forest plot of proportion of patients with refractory schizophrenia who achieve study-specific criteria of improvement following treatment with either ECT plus antipsychotic medications or antipsychotic medications alone](sap-27-04-206-g005){#sap-27-04-206-g005.tiff}

3.4. Adverse effects {#s8d}
--------------------

As shown in Table 5, six studies with a pooled sample of 534 participants reported TESS scores.\[[@B10],[@B13],[@B18],[@B20],[@B28],[@B30]\] The TESS results from these studies were quite heterogeneous, so it is only possible to provide a descriptive assessment of the results. Using the overall TESS score as the measure of the severity of adverse events, three of the studies\[[@B18],[@B28],[@B30]\] showed no significant differences between the two groups, one study\[[@B13]\] found significantly more severe adverse events in the ECT plus antipsychotic medication group, and two studies\[[@B10],[@B20]\] found significantly more severe adverse events in the group that only received antipsychotic medication.

###### 

Results for six studies that used the Treatment Emergent Symptom Scale (TESS) to assess adverse events in patients with refractory schizophrenia treated with combined electroconvulsive therapy (ECT) and antipsychotic medication versus those treated with antipsychotic medication alone

  study                  ECT + medication group               medication only group   mean difference \[95% CI\]               
  ---------------------- ------------------------ ----------- ----------------------- ---------------------------- ----------- -----------------------
  Ding, 2007\[[@B13]\]   30                       2.7 (2.4)                           30                           1.3 (1.2)   1.44 \[0.47,2.41\]
  Cai 2008\[[@B10]\]     50                       2.9 (1.6)                           50                           3.7 (2.0)   -0.76 \[-1.47,-0.05\]
  Jiang 2009\[[@B18]\]   32                       7.7 (5.9)                           35                           6.8 (5.4)   0.95 \[-1.78,3.68\]
  Yang 2011\[[@B28]\]    30                       8.2 (6.1)                           31                           7.9 (5.9)   0.34 \[-2.69,3.37\]
  Zhang 2012\[[@B30]\]   42                       5.9 (2.7)                           42                           6.9 (2.7)   -0.98 \[-2.13,0.17\]
  Jiang 2013\[[@B20]\]   81                       3.4 (0.8)                           81                           4.5 (1.1)   -1.10 \[-1.40,-0.80\]

Thirteen studies\[[@B13],[@B14],[@B15],[@B18],[@B22],[@B23],[@B26],[@B27],[@B28],[@B29],[@B30],[@B31],[@B32]\] provided information about specific adverse events. As shown in Table 6, a total of 26 kinds of adverse events were reported. Meta-analysis of the results identified two adverse effects that were reported at a significantly higher frequency by patients receiving combined treatment with ECT plus antipsychotic medication than by patients treated with antipsychotic medications alone: headache (based on a pooled sample of 517 individuals from eight studies, OR=9.10, 95%CI=3.97-20.86) and memory impairment (based on a pooled sample of 577 individuals from seven studies, OR=6.48, 95%CI=3.54-11.87).

###### 

Comparison of incidence of different adverse events in patients with refractory schizophrenia treated with electroconvulsive therapy and antipsychotic medications versus those treated only with antipsychotic medications

  events                          number of studies   participants   I^2^             p       statistical method (risk ratio)   effect estimate \[95% C\]
  ------------------------------- ------------------- -------------- ---------------- ------- --------------------------------- ---------------------------
  abnormal electrocardiogram      6                   383            32%              0.20    fixed                             0.83 \[0.58,1.19\]
  abnormal electroencephalogram   2                   123            85%              0.01    random                            1.97 \[0.31,12.65\]
  abnormal liver enzymes          7                   448            0%               0.80    fixed                             0.67 \[0.34,1.34\]
  akathisia                       4                   263            0%               0.80    fixed                             0.69 \[0.37,1.26\]
  anorexia/decreased appetite     1                   60             not applicable   fixed   2.00 \[0.19,20.90\]               
  blurred vision                  3                   203            0%               0.95    fixed                             0.92 \[0.37,2.26\]
  constipation                    6                   388            42%              0.13    fixed                             0.52 \[0.37,0.73\]
  decreased motor activity        2                   140            71%              0.06    random                            0.22 \[0.02,3.10\]
  dizziness                       5                   323            51%              0.08    random                            1.23 \[0.56,2.70\]
  drowsiness                      7                   457            61%              0.02    random                            0.71 \[0.35,1.42\]
  dry mouth                       3                   203            0%               0.85    fixed                             1.03 \[0.49,2.18\]
  Extrapyramidal symptoms         3                   182            0%               0.40    fixed                             1.74 \[0.84,3.58\]
  headache                        8                   517            7%               0.37    fixed                             9.10 \[3.97,20.86\]
  hypotension                     1                   60             not applicable   fixed   0.33 \[0.01,7.87\]                
  increased salivation            5                   328            54%              0.07    random                            0.41\[0.18,0.93\]
  insomnia                        5                   322            59%              0.05    random                            0.46 \[0.07,3.22\]
  leukopenia                      5                   336            0%               0.49    fixed                             0.31 \[0.12,0.82\]
  memory impairment               7                   577            36%              0.16    fixed                             6.48 \[3.54,11.87\]
  menstrual disorder              1                   60             not applicable   fixed   1.50 \[0.27,8.34\]                
  nasal congestion                1                   63             not applicable   fixed   3.09 \[0.13,73.17\]               
  nausea/vomiting                 5                   334            0%               0.94    fixed                             2.33 \[0.99,5.49\]
  rigidity                        2                   140            0%               0.65    fixed                             0.69 \[0.40,1.18\]
  tachycardia                     4                   268            0%               0.58    fixed                             0.77 \[0.50,1.21\]
  tremors                         2                   140            0%               0.82    fixed                             0.77 \[0.43,1.38\]
  weakness                        3                   185            0%               0.43    fixed                             0.25 \[0.11,0.59\]
  weight gain                     7                   468            4%               0.40    fixed                             0.61 \[0.43,0.87\]

3.5. Cognitive function {#s8e}
-----------------------

Five studies reported cognitive function results,\[[@B11],[@B18],[@B19],[@B23],[@B31]\] but only four of them had data that could be pooled in a meta-analysis.\[[@B11],[@B18],[@B23],[@B31]\] The meta-analysis (Figure 4) comparing the standardized mean difference (SMD) in the final scale scores between groups used the total MMSE score\[[@B41]\] for the two studies that used MMSE,\[[@B11],[@B23]\] the perseverative errors score from the WCST\[[@B42]\] for the study that used the WCST,\[[@B18]\] and the picture recognition score from the WMS\[[@B43]\] for the study that use the WMS.\[[@B31]\] The results for the study that use the WCST and for the study that used the WMS indicate significantly greater cognitive impairment in the group treated with ECT and antipsychotic medications, but when pooled with results from the two studies that use MMSE to assess cognitive functioning, the overall results were not significantly different between the two groups (SMD=-0.28, 95%CI=-0.77\~0.20). However, as stated previously (Table 4), the quality of evidence from these studies was rated as 'very low'.

![Forest plot of standardized mean difference in scores of three cognitive measures among patients with refractory schizophrenia following treatment with either ECT plus antipsychotic medications or antipsychotic medications alone](sap-27-04-206-g006){#sap-27-04-206-g006.tiff}

3.6. Overall function {#s8f}
---------------------

The meta-analysis of the three studies\[[@B9],[@B16],[@B26]\] that used the GAF to assess overall functioning at the end of the trial is shown in Figure 5. (The study that employed CGI to assess overall functioning\[[@B17]\] could not be included because the report for the study did not include a standard deviation for the mean CGI score.) For each of the three studies and for the pooled result for the studies, the overall functioning at the end of the study was significantly better in the ECT plus antipsychotic medication group than in the group treated with antipsychotic medications alone (MD=10.25, 95%CI=7.48-13.01). However,the quality of evidence for these studies was rated as 'very low' based on the GRADE criteria.

![Forest plot of mean difference in scores of the Global Assessment of Functioning scale (GAF) among patients with refractory schizophrenia following treatment with either ECT plus antipsychotic medications or antipsychotic medications alone](sap-27-04-206-g007){#sap-27-04-206-g007.tiff}

4. Discussion {#s9}
=============

4.1. Main findings {#s9a}
------------------

Since the operational definition of 'refractory schizophrenia' was first proposed by Kane in 1995,\[[@B3]\] there has been increasing research about the identification and management of these hard-totreat patients. Previous meta-analyses conclude that clozapine can improve psychiatric symptoms and decrease the occurence of extrapyramidal side effects for about half of these refractory patients.\[[@B24]\] ECT is an option for increasing the proportion of refractory patients who achieve satisfactory clinical outcomes, but there are few studies addressing this issue, possibly because of the reluctance of patients and clinicians to use ECT.

Extensive screening of English-language and Chinese-language databases identified 22 RCTs on this topic, among which 4 were in English and 18 were in Chinese, suggesting that the use of ECT as an adjunctive treatment in refractory schizophrenia is less controversial in China than abroad. The pooled result about efficacy (defined as the proportion of participants that achieved the study-specific criteria for 'improvement') included 1394 individuals that participated in 18 studies. It clearly indicated a superior clinical result for refractory patients who received combined treatment with ECT and antipsychotic medications (RR=1.25, 95% CI=1.14\~1.37). Moreover, the quality of the evidence for this outcome using the GRADE criteria was rated as 'moderate', which means that the result is reasonably robust. We also found that patients who received combined treatment were much more likely to report headaches and memory impairment during the treatment and to have higher overall functioning at the end of treatment, but the quality of evidence for these findings was rated as 'very low'.

4.2. Limitations {#s9b}
----------------

The low quality of the RCTs identified for inclusion in this review seriously limits the validity of the results, particularly the results related to the occurrence of adverse effects, cognitive impairment, and overall functioning. As shown in our assessment of the risk of bias, the main problem was that most of the reports on the included studies did not provide details about the methods employed in the study, resulting in an overall rating of the assessment of risk of bias of 'uncertain' in 21 of the 22 included studies.

The most troubling problem was lack of blinding. Double blinding is difficult to achieve in studies involving ECT because of the practical and ethical problems of administering 'sham ECT', so it is not surprising that sham ECT was only used in 1 of the 22 included studies. On the other hand,it is relatively easy to blind raters who assess the outcome measures,but this was only done in 3 of the 22 studies. We also identified a clear publication bias, favoring publication of studies that find superior outcomes among patients receiving both ECT and antipsychotic medication.

4.3. Implication {#s9c}
----------------

The current study systematically reviewed and evaluated all available RCTs about the efficacy and safety of the combined use of antipsychotics and ECT in the treatment of patients with refractory schizophrenia. Meta-analysis of the 22 identified studies found that compared to treatment with antipsychotic medications alone,combined treatment with ECT and antipsychotic medication resulted in improved clinical outcomes, higher rates of headaches and memory impairment during treatment, and better overall functioning at the end of treatment. However, given the low quality of the evidence in the studies and the existence of publication bias,these results must be considered suggestive,not definitive. Better designed studies that include more detailed description of the methods employed are needed to confirm (or disprove) these results.

Studies about the use of ECT in schizophrenia are relatively common in China, so this is one area in which China could make an important contribution to the global literature. However, Chinese mental health researchers will not be able to make useful international contributions until they resolve common problems in the design and implementation of their studies, problems that could be easily addressed by strict adherence to the recommendations for RCTs in the CONSORT statement.\[[@B5]\]
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